These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20977850)

  • 21. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
    Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
    J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
    Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA;
    JAMA; 2006 Apr; 295(13):1519-30. PubMed ID: 16537725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.
    Mukherjee D; Eagle KA
    Prog Cardiovasc Dis; 2007; 50(3):167-80. PubMed ID: 17976502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
    Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry.
    Seth A; Sinha N; Parikh K; Patel T; Hiremath MS; Mehta AB; Chandra P; Pinto B; Sethi KK; Sengottuvelu S
    Indian Heart J; 2008; 60(4):333-41. PubMed ID: 19242012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative Bleeding in Patients With Acute Coronary Syndrome Treated With Fondaparinux Versus Low-Molecular-Weight Heparin Before Coronary Artery Bypass Grafting.
    Khodabandeh S; Biancari F; Kinnunen EM; Mariscalco G; Airaksinen J; Gherli R; Gatti G; Demal T; Onorati F; Faggian G; De Feo M; Santarpino G; Rubino AS; Maselli D; Salsano A; Nicolini F; Zanobini M; Ruggieri VG; Bounader K; Perrotti A; Dalén M
    Am J Cardiol; 2019 Feb; 123(4):565-570. PubMed ID: 30527774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fondaparinux in Acute Coronary Syndromes.
    Trailokya A; Dhall A; Kumbla DK
    J Assoc Physicians India; 2015 Jul; 63(7):83-7. PubMed ID: 26731838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fondaparinux in the management of patients with ST-elevation acute myocardial infarction.
    Turpie AG
    Vasc Health Risk Manag; 2006; 2(4):371-8. PubMed ID: 17323591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
    Eikelboom JW; Anand SS; Malmberg K; Weitz JI; Ginsberg JS; Yusuf S
    Lancet; 2000 Jun; 355(9219):1936-42. PubMed ID: 10859038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    Am J Cardiovasc Drugs; 2008; 8(2):113-25. PubMed ID: 18422394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
    Budaj A; Eikelboom JW; Mehta SR; Afzal R; Chrolavicius S; Bassand JP; Fox KA; Wallentin L; Peters RJ; Granger CB; Joyner CD; Yusuf S;
    Eur Heart J; 2009 Mar; 30(6):655-61. PubMed ID: 18713759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    Joyner CD; Peters RJ; Afzal R; Chrolavicius S; Mehta SR; Fox KA; Granger CB; Franzosi MG; Flather M; Budaj A; Bassand JP; Yusuf S
    Am Heart J; 2009 Mar; 157(3):502-8. PubMed ID: 19249421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fondaparinux in the initial and long-term treatment of venous thromboembolism.
    Pesavento R; Amitrano M; Trujillo-Santos J; Di Micco P; Mangiacapra S; López-Jiménez L; Falgá C; García-Bragado F; Piovella C; Prandoni P; Monreal M;
    Thromb Res; 2015 Feb; 135(2):311-7. PubMed ID: 25543161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fondaparinux: a pharmacoeconomic review of its use in the management of non-ST-segment elevation acute coronary syndrome.
    McKeage K; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(8):687-98. PubMed ID: 20617858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.